We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis
Read MoreHide Full Article
Eli Lilly and Company (LLY - Free Report) announced that the FDA has approved its psoriasis drug Taltz (ixekizumab) for a new indication. Taltz injection (80 mg/mL) is now approved for the treatment of adult patients with ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA). This is the third indication for the drug.
Taltz was evaluated in two randomized, placebo-controlled phase III studies, which demonstrated its efficacy and safety in 657 adult patients with active AS. In both studies, Taltz achieved the primary efficacy endpoint, which was to see the proportion of patients achieving Assessment of Spondyloarthritis International Society 40 (ASAS40) response at 16 weeks of treatment compared to placebo.
Moreover, patients treated with Taltz also demonstrated statistically significant improvements in key secondary endpoints in both the studies.
AS is a type of spondyloarthritis affecting the pelvic joints and the spine.
Shares of Lilly inched up almost 2.1% following this news on Monday. However, the stock has lost 3.4% so far this year, wider than the industry’s decrease of 2.1%.
Taltz is presently marketed for moderate-to-severe plaque in adults, who are candidates for systemic therapy or phototherapy and also for those with active psoriatic arthritis (PsA).
Notably, apart from Taltz, other drugs having got the nod to treat plaque psoriasis are Novartis’ (NVS - Free Report) Cosentyx, AbbVie’s (ABBV - Free Report) Humira and Johnson & Johnson’s (JNJ - Free Report) new drug Tremfya.
Earlier this month, Lilly announced that Taltz was found superior to J&J’s Tremfya (guselkumab) in delivering total skin clearance at week 12 in a head-to-head comparison study, which evaluated the efficacy between Taltz and Temfya.
Top-line data from the study showed that a higher proportion of patients treated with Taltz achieved complete skin clearance compared to Tremfya as measured by PASI 100, thereby meeting the study’s primary endpoint.
Taltz is an important revenue driver for Lilly, generating sales of $606.3 million in the first half of 2019. The figure is up 65% year over year. The label expansion will increase the strength of eligible patient population for the drug, which should drive its sales going forward.
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Image: Bigstock
Lilly's (LLY) Taltz Gets FDA Nod for Ankylosing Spondylitis
Eli Lilly and Company (LLY - Free Report) announced that the FDA has approved its psoriasis drug Taltz (ixekizumab) for a new indication. Taltz injection (80 mg/mL) is now approved for the treatment of adult patients with ankylosing spondylitis (AS), also known as radiographic axial spondyloarthritis (r-axSpA). This is the third indication for the drug.
Taltz was evaluated in two randomized, placebo-controlled phase III studies, which demonstrated its efficacy and safety in 657 adult patients with active AS. In both studies, Taltz achieved the primary efficacy endpoint, which was to see the proportion of patients achieving Assessment of Spondyloarthritis International Society 40 (ASAS40) response at 16 weeks of treatment compared to placebo.
Moreover, patients treated with Taltz also demonstrated statistically significant improvements in key secondary endpoints in both the studies.
AS is a type of spondyloarthritis affecting the pelvic joints and the spine.
Shares of Lilly inched up almost 2.1% following this news on Monday. However, the stock has lost 3.4% so far this year, wider than the industry’s decrease of 2.1%.
Taltz is presently marketed for moderate-to-severe plaque in adults, who are candidates for systemic therapy or phototherapy and also for those with active psoriatic arthritis (PsA).
Notably, apart from Taltz, other drugs having got the nod to treat plaque psoriasis are Novartis’ (NVS - Free Report) Cosentyx, AbbVie’s (ABBV - Free Report) Humira and Johnson & Johnson’s (JNJ - Free Report) new drug Tremfya.
Earlier this month, Lilly announced that Taltz was found superior to J&J’s Tremfya (guselkumab) in delivering total skin clearance at week 12 in a head-to-head comparison study, which evaluated the efficacy between Taltz and Temfya.
Top-line data from the study showed that a higher proportion of patients treated with Taltz achieved complete skin clearance compared to Tremfya as measured by PASI 100, thereby meeting the study’s primary endpoint.
Taltz is an important revenue driver for Lilly, generating sales of $606.3 million in the first half of 2019. The figure is up 65% year over year. The label expansion will increase the strength of eligible patient population for the drug, which should drive its sales going forward.
Zacks Rank
Lilly currently carries a Zacks Rank #2 (Buy). You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
More Stock News: This Is Bigger than the iPhone!
It could become the mother of all technological revolutions. Apple sold a mere 1 billion iPhones in 10 years but a new breakthrough is expected to generate more than 27 billion devices in just 3 years, creating a $1.7 trillion market.
Zacks has just released a Special Report that spotlights this fast-emerging phenomenon and 6 tickers for taking advantage of it. If you don't buy now, you may kick yourself in 2020.
Click here for the 6 trades >>